


Challenging the status quo: unlocking new horizons for patients with HR-NMIBC after BCG treatment



Thursday 19 June 2025
16:15–16:45 CEST



Centro de Convenciones
Hotel ILUNION Alcora Sevilla
Seville, Spain

Faculty



Prof. Bernardo Herrera Imbroda
Virgen de la Victoria Hospital, Málaga
Málaga, Spain




Dr. Géraldine Pignot
Institut Paoli-Calmettes
Marseille, France

Agenda

Time (CEST)	Session title	Speaker
16:15	Welcome and introductions	Prof. Herrera Imbroda
16:20	HR-NMIBC after BCG treatment: insights from a patient case	Prof. Herrera Imbroda
16:24	At the crossroads: BCG rechallenge vs chemotherapy in BCG-unresponsive patients	Prof. Herrera Imbroda and Dr. Pignot
16:34	Beyond the horizon: current and future treatment landscape after BCG	Dr. Pignot
16:40	Q&A and closing	Dr. Pignot

BCG, Bacillus Calmette–Guérin; HR, high-risk; NMIBC, non-muscle invasive bladder cancer.

Challenging the status quo: unlocking new horizons for patients with HR-NMIBC after BCG treatment



Learning objectives

- To discuss current treatment options for patients with HR-NMIBC after BCG
- To explore strategies for the management of patients with BCG-unresponsive and BCG-exposed HR-NMIBC



Cannot attend in person?


Scan the QR code to join our live stream via the ecancer platform^a



Get involved!

- Scan the QR code to
- Participate in the live polling
 - Submit questions

Engage with the experts!



Interactive Flash Symposium with live polling and plenty of opportunities for Q&A



Tell us what you think!

Scan the QR code to complete the meeting evaluation form



Adverse event reporting

Scan the QR code to report adverse events

^a ecancer live-streaming and on-demand content are not available for HCPs from Spain.

BCG, Bacillus Calmette-Guérin; HR, high-risk; EMEA, Europe, the Middle East, and Africa; NMIBC, non-muscle invasive bladder cancer.

This industry symposium is funded and organized by Johnson & Johnson in EMEA and is intended for healthcare professionals only. Janssen Pharmaceutica NV, a Johnson & Johnson company, Turnhoutseweg 30, B-2340 Beerse, Belgium.

EM-180537 | Prepared May 2025

Johnson & Johnson

Medical Education